NCT06118333View on ClinicalTrials.gov

A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

386

Participants

Timeline

Start Date

December 4, 2023

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions
Nasopharyngeal Carcinoma
Interventions
DRUG

BL-B01D1

Administration by intravenous infusion

DRUG

capecitabine

Oral administration

DRUG

gemcitabine

Administration by intravenous infusion

DRUG

docetaxel

Administration by intravenous infusion

Trial Locations (1)

Unknown

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
collaborator

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

INDUSTRY

lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY

NCT06118333 - A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma | Biotech Hunter | Biotech Hunter